Anticonvulsants during Pregnancy and Lactation Transplacental, Maternal and Neonatal Pharmacokinetics

Clinical Pharmacokinetics

Volumn 7, Issue 6, 1982, Pages 508-543

  Nau, H ^a,b   Kuhnz, W ^a,b   Egger, H J ^a,b   Rating, D ^a,b   Helge, H ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; 2 PROPYL 2 PENTENOIC ACID; 2 PROPYL 4 PENTENOIC ACID; 2 PROPYLGLUTARIC ACID; 3 HYDROXYVALPROIC ACID; 3 OXOVALPROIC ACID; 4 HYDROXYVALPROIC ACID; 5 (2,4 DIHYDROXYPHENYL) 5 PHENYLHYDANTOIN; 5 (3,4 DIHYDROXY 1,5 CYCLOHEXADIEN 1 YL) 5 PHENYLHYDANTOIN; 5 (3,4 DIHYDROXYPHENYL) 5 PHENYLHYDANTOIN; 5 (4 HYDROXY 3 METHOXYPHENYL) 5 PHENYLHYDANTOIN; 5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; 5 HYDROXYVALPROIC ACID; AMINOPHENAZONE C 13; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; DRUG METABOLITE; ETHOSUXIMIDE; ETHYL(PHENYL)MALONAMIDE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; UNCLASSIFIED DRUG; VALPROIC ACID;

CENTRAL NERVOUS SYSTEM; DRUG BLOOD LEVEL; DRUG THERAPY; ENZYME INDUCTION; FETUS; HUMAN; HYDROXYPHENOBARBITAL; LACTATION; NEWBORN; PHARMACOKINETICS; PLACENTAL TRANSFER; PREGNANCY; REVIEW; THERAPY;

ANTICONVULSANTS; CARBAMAZEPINE; ETHOSUXIMIDE; FEMALE; FETUS; HUMANS; INFANT, NEWBORN; INTESTINAL ABSORPTION; KINETICS; LACTATION; MATERNAL-FETAL EXCHANGE; MILK, HUMAN; PHENOBARBITAL; PHENYTOIN; PLACENTA; PREGNANCY; PRIMIDONE; PROTEIN BINDING; VALPROIC ACID;

EID: 0020401577     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198207060-00003     Document Type: Review

References (105)

1. Sodium valproate and pregnancy
2. Kinetics and metabolism of phenobarbital in the neonate
3. Plasma clearances of Phenytoin, phenobarbitone, primidone and carbamazepine during pregnancy. A prospective study
4. Passage of diphenylhydantoin across the placenta
5. Clinical pharmacology of phenobarbital in the neonatal period
6. Plasma concentrations of phenobarbital in mother and child after combined prenatal and postnatal administration for prophylaxis of hyperbilirubinemia
7. Pharmacokinetics and clinical effects of anticonvulsant drugs in newborns
8. Plasma levels and clinical effects of antiepileptic drugs in pregnant epileptic patients and their newborns
9. Valproic acid dosage and plasma protein binding and clearance
10. Pharmacokinetics of dipropyl acetate in infants and young children
11. Absorption of phenobarbital after the intramuscular administration of single doses in infants
12. Modification of seizure frequency in pregnancy: prospective data in 48 patients with epilepsy
13. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age group
14. Pharmacological implications of microsomal enzyme induction
15. Pharmacological implications of microsomal enzyme induction
16. Antiepileptic drugs: metabolism in pregnancy
17. Induction of hepatic enzymes during normal human pregnancy
18. Valproate induces urinary D-glucaric acid excretion
19. Serum protein binding of drugs during and after pregnancy in humans
20. Transmission of valproic acid (Dekapene) across the placenta: Half-life of the drug in mother and baby
21. Nonlinear kinetics of phenytoin in children
22. Plasma drug level monitoring in pregnancy
23. Identification of diphenylhydantoin and its metabolites, including the dihydrodiol and the catechols in maternal plasma, placenta and fetal tissue of man
24. Metabolism of diphenyl-hydantoin in isolated hepatocyte and liver organ cultures of the human fetus
25. Determination of diphenylhydantoin and its metabolites by glass capillary GC-MS
26. Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults
27. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses
28. Body water compartments in children: changes during growth and related changes in body composition
29. Antiepileptika-Therapie während der Schwangerschaft und Geburt; in Remschmidt
30. Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. 1. Differences in mutagenicity
31. Clinical pharmacokinetics of valproic acid
32. Serum protein binding of drugs and bilirubin in newborn infants and their mothers
33. Pharmacokinetics of phenobarbital in childhood
34. Pharmacokinetics in the human neonate
35. 13C-dimethylaminopyrine in children
36. Drug metabolism in the human neonate
37. Placental transfer of anticonvulsants (phenobarbital, Phenytoin, valproic acid) and the elimination from neonates
38. Disappearance from the newborn of circulating prenatally administered phenobarbital
39. Drug metabolism by the human fetus
40. The levels of anticonvulsants in breast milk
41. The problems of anticonvulsant medication at the neonatal period: Is breast feeding advisable
42. Phenytoin metabolism in pregnancy
43. Ethosuximide pharmacokinetics in a pregnant patient and the newborn
44. Drug disposition and pharmacokinetics in the maternal placental fetal unit
45. Differences in the binding of drugs to plasma proteins from newborn and adult man. I
46. Plasma anticonvulsant concentrations during pregnancy
47. Metabolism of diphenylhydantoin (Phenytoin) during pregnancy
48. Drug metabolism in cultures of isolated hepatocytes of the human fetus, the newborn pig and the adult rat
49. An improved method for the preparation of human fetal and adult hepatocytes
50. Pharmacokinetic observations of Phenytoin disposition in the newborn and young infant
51. Transplacental passage of primidone
52. Placental transfer of phenobarbitone in epileptic women, and elimination in newborns
53. Placental transfer and neonatal elimination of diphenylhydantoin
54. Diphenylhydantoin: Placental transport, fetal localization, neonatal metabolism, and possible teratogenic effects
55. Clinical pharmacokinetics in neonates
56. Antiepileptic drugs
57. Clinical pharmacokinetics of antiepileptic drugs in adults
58. Clinical pharmacokinetics in newborns and infants
59. Phenytoin and phenobarbitone plasma clearance during pregnancy
60. Liver organ culture as a long term viable system for the study of drug metabolism in the human fetus
61. Drug metabolism and lipid peroxidation in various hepatic in vitro systems of the human fetus
62. Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers
63. Development of drug-metabolizing monooxygenase systems in various mammalian species including man. Its significance for transplacental toxicity
64. Pharmacokinetics of primidone and metabolites during human pregnancy
65. Placental transfer at birth and postnatal elimination of primidone and metabolites in neonates of epileptic mothers
66. Pharmacokinetics of valproic acid and its metabolites in a pregnant patient: stable isotope methodology
67. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers
68. Placental transfer and neonatal pharmacokinetics of valproic acid and some of its metabolites
69. Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by GC-MS selected ion monitoring
70. Carbamazepine levels in pregnancy and lactation
71. Phenobarbital and diphenylhydantoin levels in neonates with seizures
72. Biotransformation of xenobiotics in the fetus
73. Ultra-structure of human liver at the end of normal pregnancy
74. Studies on the accumulation of certain barbiturates in the brain of the human fetus
75. Altered drug binding to serum proteins in pregnant women: therapeutic relevance
76. The epileptic mother and her child
77. Formation of carbamazepine epoxide in human fetal liver
78. Phenobarbital pharmacokinetics in neonates
79. Neonatal pharmacokinetics of valproic acid
80. On the transfer of barbiturates to the human fetus and their accumulation in some of its vital organs
81. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk
82. Status epilepticus in pregnancy: effect of Phenytoin malabsorption on seizure control
83. Urinary excretion of diphenylhydantoin metabolites in newborn infants
84. Disposition of placentally transferred carbamazepine (Tegretol) in the newborn
85. Plasma disappearance of transplacentaly transferred diphenylhydantoin in the newborn studied by mass fragmentography
86. Kinetics of placentally transferred Phenytoin and its p-hydroxylated metabolites in newborn infants
87. Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants
88. Oxidative and synthetic drug-metabolic pathways in the newborn infant. Studies on the neonatal kinetics of oxazepam
89. Ethosuximide in human milk and in plasma of a mother and her nursed infant
90. Enzyme induction in neonates due to antiepileptic therapy during pregnancy
91. Minor anomalies in the offspring of epileptic parents (prospective study)
92. Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women
93. Antiepileptika Während Schwangerschaft und Stillzeit
94. Pharmacokinetics of carbamazepine in the neonate and in the child
95. Urinary corticosteroid and diphenylhydantoin metabolite patterns in neonates exposed to anticonvulsant drugs in utero
96. Phenytoin binding in pregnancy
97. The effect of pregnancy on the natural history of epilepsy
98. Sodium valproate, pregnancy and neonatal hyperglycinaemia
99. Anticonvulsant toxicity in vitro; possible role of arene oxides
100. Drug disposition in pregnancy
101. Serum protein binding of valproic acid in healthy subjects and patients with liver disease
102. Kinetics of drug interactions in the treatment of epilepsy
103. Stillen und Medikamente
104. 13C-labelled valproic acid pulse dosing during steady state antiepileptic therapy for pharmacokinetic studies during pregnancy